Patents for A61P 35 - Antineoplastic agents (221,099)
02/2003
02/04/2003CA2109815C Antibody preparation
02/03/2003WO2002016312A2 Novel compounds inhibiting factor xa activity
02/03/2003CA2418283A1 Novel compounds inhibiting factor xa activity
01/2003
01/31/2003CA2354486A1 C7 ester substituted taxanes
01/31/2003CA2354478A1 C10 carbonate substituted taxanes
01/31/2003CA2354471A1 C10 ester substituted taxanes
01/30/2003WO2003008966A1 Preventives/remedies for cancer and diagnostics
01/30/2003WO2003008649A1 Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin
01/30/2003WO2003008644A1 Method of screening abc protein promoter/inhibitor
01/30/2003WO2003008595A2 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression
01/30/2003WO2003008581A1 p53-DEPENDENT APOPTOSIS-INDUCING PROTEIN AND METHOD OF SCREENING APOPTOSIS REGULATOR
01/30/2003WO2003008579A2 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby
01/30/2003WO2003008578A2 Reagents and methods for identifying gene targets for treating cancer
01/30/2003WO2003008576A2 Synthetic double stranded oligonucleotides for targeted inhibition of gene expression
01/30/2003WO2003008573A2 Silencing of gene expression by sirna
01/30/2003WO2003008537A2 Epitope sequences
01/30/2003WO2003008457A2 Polysaccharidic esters of retinoic acid
01/30/2003WO2003008450A1 Tumor antigen
01/30/2003WO2003008449A1 Ntb-a, a surface molecule involved in natural killer cells activity
01/30/2003WO2003008448A2 Novel human proton-gated channels
01/30/2003WO2003008446A1 Polypeptides relating to signal transfer of advanced glycation end product receptor
01/30/2003WO2003008444A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
01/30/2003WO2003008443A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
01/30/2003WO2003008430A2 Porphyrin derivatives for photodynamic therapy
01/30/2003WO2003008429A2 Solvent-free anthracycline derivatives
01/30/2003WO2003008425A1 Novel bisphosphonate derivatives, their preparation methods and uses
01/30/2003WO2003008423A1 New antitumoral derivatives of et-743
01/30/2003WO2003008410A2 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression
01/30/2003WO2003008409A1 Quinoline derivatives and their use as tyrosine kinase inhibitors
01/30/2003WO2003008407A2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
01/30/2003WO2003008399A1 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
01/30/2003WO2003008395A1 Substituted isoxazoles and the use thereof as antibiotics
01/30/2003WO2003008394A1 Novel chelating agents and conjugates thereof, their synthesis and use as diagnostic and therapeutic agents
01/30/2003WO2003008392A1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies
01/30/2003WO2003008390A1 Multidentate aza ligands able to complex metal ions and the use thereof in diagnostics and therapy
01/30/2003WO2003008388A1 I-form crystal of n-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-n'-propylurea and process for producing the same
01/30/2003WO2003008384A1 Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands
01/30/2003WO2003008379A1 Azasugar compounds
01/30/2003WO2003008378A1 Dolastatin 10 derivatives
01/30/2003WO2003008374A1 Inhibitors of the ice/ced-3 family of cysteine proteases
01/30/2003WO2003008371A1 Substituted 4-aminocyclohexanol derivatives
01/30/2003WO2003008365A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
01/30/2003WO2003008005A2 Catheter and implants for the delivery of therapeutic agents to tissues
01/30/2003WO2003007993A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor
01/30/2003WO2003007988A1 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan
01/30/2003WO2003007987A2 Haptenizing cancer cell components for the preparation of cancer vaccines
01/30/2003WO2003007978A1 Alpha-fetoprotein peptides and uses thereof
01/30/2003WO2003007976A1 High protein, bowman-birk inhibitor concentrate and process for its manufacture
01/30/2003WO2003007971A1 Improved heteropolymer complexes and methods for their use
01/30/2003WO2003007961A1 Methods for treating neoplastic, angiogenic, fibroplastic, and/or immunosuppresive ocular irregularities via administration of methotrexate based medicaments, and ocular iontophoretic devices for delivering methotrexate based medicaments
01/30/2003WO2003007957A1 Method and composition for treatment of cancer
01/30/2003WO2003007955A2 Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
01/30/2003WO2003007954A2 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
01/30/2003WO2003007950A1 (pyridinyl and pyrimidyl) trienoic acid derivatives as retinoid x receptor modulators
01/30/2003WO2003007943A1 Kinase inhibitors and the use thereof
01/30/2003WO2003007942A1 Substituted isoindoles and the use thereof
01/30/2003WO2003007937A1 Antitumor agent containing cyclic polylactic acid
01/30/2003WO2003007933A1 Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer's and related neurodegenerative disorders
01/30/2003WO2003007931A1 Sulfonamide derivatives
01/30/2003WO2003007930A2 Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
01/30/2003WO2003007927A1 Synthesis and functin inhibitors for heat shock proteins
01/30/2003WO2003007924A2 Combinations comprising epothilones and pharmaceutical uses thereof
01/30/2003WO2003007915A2 Compositions for treatment of head and neck cancers, and methods of making and using the same
01/30/2003WO2003007890A2 Tropomyosin isoforms, and diagnostic and therapeutic uses therefor
01/30/2003WO2003007889A2 Therapeutic agents comprising pro-apoptotic proteins
01/30/2003WO2003007888A2 Fat accumulation-modulating compounds
01/30/2003WO2003007884A2 Method and reagents for identifying gene targets for treating breast cancer
01/30/2003WO2003007883A2 Acylsemicarbazides as cyclin dependent kinase inhibitors useful as anti-cancer and anti-proliferative agents
01/30/2003WO2003007882A2 Method of making bowman-birk inhibitor product
01/30/2003WO2003007880A2 Inhibition of behab cleavage and primary central nervous system (cns) tumors
01/30/2003WO2003007874A2 Anti-tumor activity from reptile serum
01/30/2003WO2003007869A2 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres
01/30/2003WO2003007800A2 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer
01/30/2003WO2003007798A2 Ophthalmic use of 5 fluorourcil
01/30/2003WO2003007794A2 Invasion complex and methods of targeting
01/30/2003WO2003007689A2 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids
01/30/2003WO2003007686A2 Use of copper chelators to inhibit the inactivation of protein c
01/30/2003WO2002088079A3 Dual inhibitors of pde 7 and pde 4
01/30/2003WO2002079478A3 Modification of organelle metabolism by a composition comprising unc-51-like kinases, roma1, or 2tm polypeptides and uses thereof for the preration of a medicament for the treatment disorders
01/30/2003WO2002068585A9 Tip39 polypeptides
01/30/2003WO2002066075A3 Biotin-derivatives and their conjugates with chelating agents
01/30/2003WO2002064160A8 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
01/30/2003WO2002060449A3 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates
01/30/2003WO2002057271A3 Thienopyrimidine-based inhibitors of the src family
01/30/2003WO2002051435A3 New therapeutic uses of smr1 peptides
01/30/2003WO2002034879A3 Method for introducing antisense oligonucleotides into eucaryotic cells
01/30/2003WO2002029035A3 Method to alter sugar moieties
01/30/2003WO2002026215A3 Thermogelling biodegradable aqueous polymer solution
01/30/2003WO2002018376A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
01/30/2003WO2002018375A1 Quinazolines, medicaments, which contain these compounds and which are effective as tyrosine kinase inhibitors, their use, and methods for the production thereof
01/30/2003WO2002018351A1 Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof
01/30/2003WO2002017897A3 Methods for treating tumors using sulfonyl compounds
01/30/2003WO2002016567A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
01/30/2003WO2002014536A3 Odulating multiple lineage kinase proteins
01/30/2003WO2002014356A3 Therapeutic use of a recombinant erythropoietin having high activity and reduced side effects
01/30/2003WO2002013836A1 Preventive or therapeutic drugs for cancers containing cyanidin compounds as the active ingredient
01/30/2003WO2002010393A3 Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
01/30/2003WO2002009719A1 Antitumor agents
01/30/2003WO2002006267A3 Synthesis and biological evaluation of analogs of the antimitotic marine natural product curacin a
01/30/2003WO2002003071A3 Modulators of trk protein activity, compositions and uses